TLDR
- Novo Nordisk stock rose over 3% after the FDA sent warning letters to 30 telehealth companies over misleading GLP-1 drug claims.
- The companies falsely advertised compounded semaglutide and tirzepatide as “generic” versions of brand-name drugs like Wegovy and Zepbound.
- This is the FDA’s second round of such letters, following a September crackdown under Trump’s directive on drug advertising.
- Firms must respond in writing within 15 working days outlining how they’ll fix the violations.
- Citi Research flagged the letters as carrying extra weight, pointing to the FDA’s earlier referral of Hims & Hers to the DOJ.
Novo Nordisk stock climbed more than 3% on Wednesday after the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 drugs.
The letters targeted companies that advertised compounded semaglutide and tirzepatide products using language like “generic Zepbound” or “generic Mounjaro.” Those are brand names for Eli Lilly’s tirzepatide drugs.
Some firms also branded the drugs under their own trademarks without disclosing they were the compounder. The FDA said this made it appear as though they were the actual manufacturer.
The agency was clear: compounded drugs are not FDA-approved, and they are not the same as generic drugs.
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to compound drugs in a way that circumvents FDA’s approval process,” FDA Commissioner Marty Makary said in a statement.
Semaglutide is the active ingredient in Novo Nordisk’s Wegovy and Ozempic. Tirzepatide is used in Eli Lilly’s Zepbound and Mounjaro. A small number of firms were also cited for misleading claims about liraglutide, sold by Novo Nordisk as Saxenda.
Second Round of FDA Action
This is the second wave of warning letters since the FDA launched its crackdown in September. That earlier round targeted companies including Eli Lilly, Novo Nordisk, and telehealth firm Hims & Hers Health.
The current action comes under President Trump’s directive to crack down on direct-to-consumer drug advertising. The FDA said it has now sent thousands of such letters over the past six months — more than the total from the entire preceding decade.
Companies that received letters have 15 working days to respond in writing and outline steps to correct the violations.
Hims & Hers has been a recurring name in this crackdown. The FDA warned in February that it could take action over the company’s $49 compounded weight-loss pill. Novo Nordisk then sued the company that same month.
The FDA also referred Hims & Hers to the Department of Justice in early February.
What Analysts Are Saying
Citi Research said the latest letters carry more weight than usual given the escalating regulatory environment.
The brokerage pointed to the DOJ referral as a sign that heavier consequences could follow for non-compliant firms.
Citi also noted that Commissioner Makary has separately signaled intent to restrict the active pharmaceutical ingredients used in compounded GLP-1 products. That move would further tighten the market for compounders.
The timing adds pressure ahead of broad Medicare access for GLP-1s, which is expected in the second quarter.
Novo Nordisk stock was up 3.59% on the day as of Wednesday’s session.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
